Strides Pharma Global, the wholly-owned subsidiary of Strides Shasun, has received approval for Nystatin and Triamcinolone Acetonide ointment and Piroxicam capsules, used to treat fungal skin infections.
Strides got the nod from the US Food and Drug Administration (FDA) a few days after receiving an approval to market the Hepatitis and HIV drug in the US.
This product is an important new addition to Strides’ portfolio of oral solid dosage products and the Bengaluru manufacturing plant supports several current and future topical submissions for the US market, the company said.
The product will be marketed by Strides Pharma Inc. in the US market.
The US market for Piroxicam is approximately $11 million and for Nystatin and Triamcinolone Acetonide ointment USP, 0.1 per cent is about $18 million, according to the IMS sales data.